Fox Business - The Power to Prosper
Search Site

Biogen Idec

Investing lessons from the biotech rout

The Healthcare Model on Covestor had a challenging month in March and into early April, 2014.  As of April 3, 2014, the model while down 6.3% for the prior 30 days. Over a 90-day period, the portfolio is up 11% and, on a  trailing 365 day basis, it's up 44.3% as of April 3, 2014.This portfolio had a good ride with some of the bigger biotech names like Alexion ( ALXN ), Celgene ( CELG ), Biogen Idec ( BIIB ), Illumina ( ILMN ), and Gilead ( GILD ).  Recent biotech purchases like Vanda ( VNDA ), Salix ( SLXP ) also came under intense selling pressure during the month’s now infamous biotech rout .This month tested my manager skills. With some of my top stocks declining, should I stay put or move aside?  Like the Wisconsin Badger’s Frank Kaminsky who learned to pivot to help get his team to the quarter-finals of the NCAA March Madness basketball tournament, I also tried to employ the Wisconsin ‘pivot’ in investing.My first instinct as my leading holdings started breaking down was to sell a...

Read More

  1. Biotech ETFs Plummeting (XBI, IBB, BBH)

    A sector that does not appear to be linked to the government shutdown and the recent selling is taking a big hit the last few days. The biotech stocks are coming und...

  2. Isis Pharma, Biogen Idec to Tackle Brain Disorders

    Isis Pharmaceuticals (NASDAQ:ISIS) said Monday it has joined forces with Biogen Idec (NASDAQ:BIIB) in a collaboration designed to advance the treatment for neurologi...

  3. Biotech Breakout Highlights Flawed ETF Thinking

    After a shallow, and it should be emphasized it was quite shallow, pullback last month, the biotechnology sector is flexing its muscles once again.The other thing th...

  4. Perrigo to Buy Ireland's Elan

    U.S. generic drugmaker Perrigo agreed to buy fellow drug company Elan for $8.6 billion on Monday in a deal that will hand it royalty rights from a blockbuster treatm...

  5. Perrigo In $8.6 Billion Cash, Stock Deal For Elan

    Health-care products group Perrigo Co. said Monday that it has entered into a definitive agreement to buy Ireland-based Elan Corp. in a cash-and-stock deal valued at...

  6. Health Care ETFs Looking Healthy Ahead of Earnings

    Although the market is awash in earnings reports from the financial services sector, profit updates from another one of 2013's top-performing sectors will start tric...

  7. Health Care ETFs Looking Healthy Ahead of Earnings

    Although the market is awash in earnings reports from the financial services sector, profit updates from another one of 2013's top-performing sectors will start tric...

  8. Market Wrap for Wednesday, June 12: Stock and Bond Markets Fall Mid-Week; Liquidity Concerns Remain a Focus

    The U.S. stock market fell on Wednesday for the third straight session as investors continued to mull the timeline for the Federal Reserve to ratchet down its stimul...

  9. Elan Rejects Latest Royalty Pharma Approach

    Elan Corp. (ELN, DRX.DB) Thursday rejected the most recent approach by New York-based pharmaceutical investor Royalty Pharma AG, which values the company at around $...

  10. Dissident Holder First Manhattan Adds Three to Vivus Board Slate

    Dissident Vivus Inc. (VVUS) shareholder First Manhattan Co. nominated three more director candidates following the drug maker's expansion of its board size.Vivus rec...

  11. Elan rejects Royalty's $6.4 billion raised offer

    Elan rejected Royalty Pharma's increased $6.4 billion bid on Thursday, shortly after the U.S. firm cut the acceptance bar for its latest offer to 50 percent plus one...

  12. Royalty Pharma Lowers Acceptance Threshold For Elan Offer

    Royalty Pharma AG, the New York-based pharmaceutical investor bidding around $6.4 billion in cash for drugmaker Elan Corp. (ELN) Thursday said it was lowering the th...

  1. Don't Panic Over the Recent Tech Turmoil

    U.S. investors have understandably been disturbed by the dramatic selling that has slapped down high-flying momentum stocks in the Internet and biotech sectors.Tesla...

  2. Biotech ETFs Come Back Down To Earth

    Biotech stocks have been one of the hottest sectors of the market over the last several years and many exchange traded funds have benefitted greatly from their succe...

  3. Keurig Green Mountain Pops on S&P 500 Invite

    Shares of Keurig Green Mountain (NASDAQ:GMCR) cruised 3% higher Monday morning  as Wall Street cheers the company's invitation to join the S&P 500.Late Friday, McGra...

  4. Biotech And Natural Gas ETFs On A Roll

    Shares of the following exchange traded funds are trading more than 20 percent higher than 90 days ago, and they are within 10 percent of their 52-week highs.This se...

  5. Three ETFs To Buy On The Pullback (PJP, SKYY, SPY)

    The stock market pulled back like clockwork over the last few weeks as the S&P 500 fell six percent from an all-time high to the low on Wednesday.Looking back at the...

  6. Biogen Idec 4Q earnings

    Earnings HQ: FBN’s Jo Ling Kent breaks down Biogen Idec ’s fourth-quarter earnings report.

  7. Biogen Profit Rises as New Drug Shines

    Biogen Idec Inc said on Wednesday its new, high-profile oral multiple sclerosis drug Tecfidera had sales of $398 million in the fourth quarter, easily exceeding esti...

‹ Prev12345Next ›
Freebase CC-BY
Source: Biogen Idec on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL